PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced its plans to increase its team of collaborating scientists developing a new cinnamon derived compound for type-2 diabetes, one of the leading causes of death and illness worldwide.
